Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288892 | 0.92 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241537 | 0.89 | GPR119 (0.67) | GPR119CYP2C9 | |
| SCHEMBL386787 | 0.87 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391292 | 0.86 | GPR119 (0.77) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241539 | 0.86 | GPR119 (0.85) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389552 | 0.84 | GPR119 (0.75) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391183 | 0.84 | GPR119 (0.75) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389816 | 0.84 | GPR119 (0.75) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241555 | 0.84 | GPR119 (0.84) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241594 | 0.84 | GPR119 (0.85) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382203-B1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8410122-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410122-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110263624-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263624-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263624-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, BDKRB2 | GPR119 1/4885CYP2C9 736/4885KCNH2 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.